Business Wire

SOLNET-GROUP

16.1.2024 08:01:34 CET | Business Wire | Press release

Share
Solnet Group Report: Proactive Safety Measures Protect Value of Solar Investments

Solnet Group, a leading provider of smart solar energy solutions for commerce and industry, has released a new report addressing the critical issue of safety in rooftop solar installations. Titled "Safety and Security in C&I Rooftop PV,” the white paper outlines the most important considerations rooftop solar owners and installers can take to minimize risk and protect their investments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115915852/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

High-quality installers and components reduce risks later (Photo: Business Wire)

According to an audit by Clean Energy Associates, 97% of rooftop solar installations have major safety concerns. Solar panels that are improperly installed or maintained contribute not only to physical safety hazards such as fires but also to power outages and financial losses. A thorough understanding of these risks is necessary as more companies install rooftop solar to mitigate high energy costs and comply with new regulations. Against this backdrop, Solnet Group has compiled a review of risk-reducing technologies and best practices, focusing on how safety can impact the bottom line.

Safety in solar is highly relevant

The revised European Union’s Energy Performance of Buildings Directive will require rooftop solar on all new commercial buildings by 2026, and in renovated commercial buildings by 2027. Beyond this, up to 28% of European companies plan to voluntarily install a solar system within the next 3 years. With rapid growth in the number of solar installations, the risks grow as well. For businesses entering this market, a balance must also be found between upfront installation costs and the long-term operational costs of the array. By considering safety measures from the outset, companies can reduce both risks and costs by minimizing performance issues, keeping insurance premiums low, and mitigating disruptions.

Key findings

1. Safety is a prerequisite for investor confidence: A proactive approach to reducing risk enhances the lifespan of the array and ensures consistent energy generation. In turn, the project generates more value over its lifetime, creating assurance that rooftop solar systems are a viable investment.

2. High-quality installers and components reduce risks later: Comprehensive analyses of solar panel fires from both Germany and the UK indicate that installer error is one of the leading causes of fire incidents, illustrating the importance of a careful installation process. The right components can also mitigate fire risks and other hazards from electrical arcs. Power optimizers, which enable the panel field to be made voltage-free to facilitate firefighting and rescue operations, are increasingly required by insurers as a safety measure in solar installations.

3. Smart monitoring and maintenance tools contribute to a higher safety standard: Real-time monitoring and data analysis tools, coupled with automatic rapid shutdown, allow threats to be addressed right away. As a result, damage is minimized or even avoided, and the operator has a clearer overview of how the system is functioning. The international Zurich Insurance company has recently recommended smart solar systems in part due to the features of their panel-level power optimizers, which can be operated through remote control.

"The rationale behind Solnet’s focus on smart solar technology is not just efficiency; it's about ensuring our solar systems' quality, safety, and longevity. By incorporating features like continuous monitoring and protection mechanisms, we are elevating the safety standards of rooftop solar installations. Our report sheds light on the role of safety improvements in protecting investments and furthering the energy transition," says Arttur Kulvik, SVP Business Development at Solnet Group.

Solnet Group prioritizes safety in every stage of the design, installation, operations, and maintenance of its solar arrays. The company includes power optimizers and a suite of remote monitoring tools, including immediate fault detection alerts, as standard features in its smart solar systems.

The full report is available for download here. Solnet Group will also host a webinar on safety in commercial and industrial rooftop PV, together with representatives from SolarEdge and Zurich Insurance. Registration is open until January 18th.

The speakers at this webinar include Georg Stockschläder, RE Global Practice Leader Property at Zurich Insurance; Chris Voet, Key Accounts Director at Solar Edge; and Arttur Kulvik, SVP Business Development at Solnet Group.

About Solnet Group:

Established in 2014, Solnet Group is a rapidly growing solar energy company with units in the Netherlands, Germany, and Finland. In 2020, the company was listed as the 59th fastest-growing company in Europe on the Financial Times FT1000 list and ranked third in the energy sector. As early as 2016, Solnet Group received the Climate Solver award from WWF. Solnet Group offers comprehensive and high-quality services from consulting and planning to installation throughout Europe. To facilitate our clients' projects, we also provide services for project financing, solar plant maintenance, and repairs. Solnet Group's clientele includes major investment funds, shopping centers, retailers, as well as storage and logistics companies. For more information, visit www.solnet.group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240115915852/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye